Clinical trials: Age Related Maculopathy
Age-related Macular Degeneration
A Study to Assess the Safety, Tolerability and Effectiveness of MT-0814 for the Treatment of Age-related Macular Degeneration
Age-related macular degeneration (AMD) is the leading cause of blindness among adults in North America. The current standard of care for patients with exudative ("wet") AMD is anti-vascular endothelial growth factor (anti-VEGF)…
- Trial name
- NCT03869684
- Testing
- MT-0814
- Where
- 13 sites in United States
- Volunteers
- 13 people
- Sponsor
- Senju Pharmaceutical Co., Ltd.
Neovascular Age-related Macular Degeneration
Regulatory Post-Marketing Surveillance Study for Brolucizumab
This study is an open-label, multicenter, single-arm, observational post-marketing surveillance.
- Trial name
- NCT04985487
- Testing
- brolucizumab
- Where
- 28 sites in South Korea
- Volunteers
- 3,000 people
- Sponsor
- Novartis Pharmaceuticals
Age Related Macular Degeneration
Correlation Between Visual Field Defects on Foresee Preferential Hyperacuity Perimeter(PHP) and on Optical Coherence Tomography (OCT) in Patients With Choroidal Neovascularization (CNV)
Study come to investigate the correlation between visual fields (VF) defects map generated by preferential hyperacuity perimeter (PHP) and features of the choroidal neovascular lesions (CNV) demonstrated by Optical Coherence…
- Trial name
- PHP (NCT00692887)
- Testing
- PHP - Preferential Hyperacuity Perimeter (Foresee)
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- Notal Vision Ltd.
Choroidal Neovascularization, Age-Related Maculopathy
Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)
The study will evaluate the safety and efficacy of the intravitreal dexamethasone implant as adjunctive therapy to Anti-VEGF treatment in the study eye of treatment naïve subjects with choroidal neovascularization secondary to…
- Trial name
- NCT00775411
- Testing
- dexamethasone, ranibizumab
- Where
- 3 sites in United States, Australia and 1 more
- Volunteers
- 44 people
- Sponsor
- Allergan
Neovascular (Wet) Age-related Macular Degeneration
A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment
Researchers are looking for a better way to treat people who have neovascular (wet) age-related macular degeneration (nAMD or wet AMD).
- Trial name
- XPAND (NCT05473715)
- Testing
- Aflibercept(BAY86-5321, Eylea)
- Where
- 3 sites in Canada, United Kingdom
- Volunteers
- 3 people
- Sponsor
- Bayer
Geographic Atrophy, Dry Age Related Macular Degeneration
Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration
The purpose of this phase II study is to determine the efficacy of fenretinide in the treatment of geographic atrophy (GA) in subjects with the dry form of age-related macular degeneration (AMD).
- Trial name
- NCT00429936
- Testing
- Fenretinide
- Volunteers
- 245 people
- Sponsor
- Sirion Therapeutics, Inc.
Wet Age-related Macular Degeneration
A Study to Compare JL14002 to Lucentis® in Subjects With Wet Age-related Macular Degeneration (wAMD)
This is a randomised, double-masked, parallel group, multicentre study to evaluate the efficacy and safety of JL14002 compared to Lucentis® in subjects with wAMD.
- Trial name
- NCT07389577
- Testing
- JL14002 monoclonal antibody(Fixed dosing regimen), Ranibizumab(Fixed dosing regimen), JL14002 monoclonal antibody(PRN)
- Where
- China
- Volunteers
- 443 people
- Sponsor
- Jecho Biopharmaceuticals Co., Ltd.
Neovascular Age-Related Macular Degeneration (nAMD)
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)
This interventional study is being conducted with an investigational gene therapy treatment called ABBV-RGX-314 (also known as RGX-314) and is being developed as a potential one-time gene therapy treatment for neovascular (wet)…
- Trial name
- AAVIATE (NCT04514653)
- Testing
- Ranibizumab, ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2
- Where
- 18 sites in United States
- Volunteers
- 146 people
- Sponsor
- AbbVie
Macular Degeneration
A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration
This is a safety and efficacy study of abicipar pegol in patients with neovascular age-related macular degeneration to establish comparability between Japanese and non-Japanese.
- Trial name
- NCT02181504
- Testing
- abicipar pegol, ranibizumab
- Where
- 11 sites in Japan
- Volunteers
- 25 people
- Sponsor
- Allergan
Macular Degeneration
A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration
This is a safety and efficacy study of abicipar pegol in patients with neovascular age-related macular degeneration to establish comparability between Japanese and non-Japanese.
- Trial name
- NCT02181517
- Testing
- abicipar pegol, ranibizumab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Allergan
Macular Degeneration
An Extension to Study MD7108240
This is a two month study to allow continued treatment with pazopanib eye drops. Study may be extended to 5 months.
- Trial name
- NCT00733304
- Testing
- Pazopanib
- Where
- 17 sites in United States, Australia and 1 more
- Volunteers
- 42 people
- Sponsor
- GlaxoSmithKline
Neovascular Age-related Macular Degeneration
Efficacy And Safety Of Macugen In Patients With Neovascular AMD In Routine Clinical Practice.
Efficacy and safety of MACUGEN in patients suffering from neovascular age-related macular degeneration in routine clinical practice at least as good as demonstrated in randomized multicenter clinical trials.
- Trial name
- MACULA (NCT00858208)
- Testing
- pegaptanib sodium
- Where
- 8 sites in Greece
- Volunteers
- 86 people
- Sponsor
- Pfizer
AMD
Post-Approval Study of the Implantable Miniature Telescope
The objective of the PAS-01 study is to assess the safety of the intraocular as measured by the cumulative incidence of patients who within 5 years after implantation experience persistent vision-impairing corneal edema (corneal…
- Trial name
- PAS-01 (NCT01757132)
- Testing
- Implantable Miniature Telescope
- Where
- 16 sites in United States
- Volunteers
- 770 people, healthy volunteers welcome
- Sponsor
- VisionCare, Inc.
Neovascular Age-related Macular Degeneration
A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD
This study is designed for Open-label, multi-center, single-arm Phase II trail to evaluate the efficacy and safety of intravitreal injection of IBI302 in nAMD patients.
- Trial name
- NCT07275840
- Testing
- IBI302 8mg dose
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Innovent Biologics Technology Limited (Shanghai R&D Center)
Macular Degeneration, Age-related Macular Degeneration
A Study To Evaluate The Safety, Tolerability And Pk Of Pazopanib Eye Drops In Healthy Adult And Elderly Subjects.
This is a two-part study to evaluate the safety, tolerability and pharmacokinetics of single (Part A) and repeat (Part B) eye drop doses of pazopanib in healthy adult and elderly subjects.
- Trial name
- NCT00463320
- Testing
- Pazopanib eye drops and Allergen Refresh Plus eye drops
- Where
- 2 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Macular Degeneration
Randomized, Single-Masked, Long-Term, Safety and Tolerability Study of VEGF Trap-Eye in AMD
Rollover study for subjects in prior VEGF Trap-Eye Phase I and II studies. Primary objective is to assess long-term safety and tolerability of continuing intravitreal treatment in subjects with wet age-related macular…
- Trial name
- NCT00527423
- Testing
- VEGF Trap Eye
- Where
- 33 sites in United States
- Volunteers
- 157 people
- Sponsor
- Regeneron Pharmaceuticals
Dry Age-related Macular Degeneration
Feasibility Study of Compensation for Blindness With the PRIMA System in Patients With Dry Age Related Macular Degeneration
In this study, the principle functionality of the device will be tested in humans for the first time. The study will evaluate the extent to which patients with atrophic dry age related macular degeneration (AMD) have evoked light…
- Trial name
- PRIMA FS (NCT03333954)
- Testing
- PRIMA Bionic Vision System
- Where
- France
- Volunteers
- 5 people
- Sponsor
- Science Corporation
Wet Macular Degeneration, Neovascular Age-related Macular Degeneration
A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular Age-related Macular Degeneration (AMD)
The goal of this clinical trial is to compare the safety and effect on visual acuity of three different doses of SYL1801 eye drops.
- Conditions
- Wet Macular Degeneration, Neovascular Age-related Macular Degeneration, Macular Degeneration
- Trial name
- NCT05637255
- Testing
- SYL1801
- Where
- 16 sites in Czechia, Poland and 1 more
- Volunteers
- 99 people
- Sponsor
- Sylentis, S.A.
Age-related Macular Degeneration (AMD)
Characteristics of Patients With Neovascular Age-related Macular Degeneration Enrolled in the Brolucizumab Patient Support Services Program
The study was a retrospective, cross-sectional, descriptive study of patients with wet AMD who enrolled in the brolucizumab Patient Support Services (PSS) program.
- Trial name
- NCT05066685
- Testing
- All participants
- Where
- United States
- Volunteers
- 18,457 people
- Sponsor
- Novartis Pharmaceuticals
Age-related Macular Degeneration
Comparison of Safety, Effectiveness and Quality of Life Outcomes Between Labeled Versus "Treat and Extend" Regimen in Turkish Patients With Choroidal Neovascularisation Due to Age-related Macular Degeneration (AMD)
The purpose of the study was to compare 2 treatment regimens for patients suffering from choroidal neovascularisation secondary to age-related macular degeneration (AMD).
- Trial name
- SALUTE (NCT01148511)
- Testing
- Ranibizumab 0.5 mg
- Where
- 8 sites in Turkey (Türkiye)
- Volunteers
- 99 people
- Sponsor
- Novartis Pharmaceuticals